Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
The purpose of this study is to test whether the timing of meals can improve treatment adverse events, influence tumor biology and alter a person's mood and behaviors.
• Any sex/gender of any ethnic/racial background
• Age greater than or equal to 18 years
• Histologically-confirmed rectal cancer stage II, III, or IV (if curative) or human epidermal growth factor receptor 2-positive (HER2+) or triple negative breast cancer stage I, II, or III (only if definitive intent) per American Joint Committee on Cancer (AJCC) criteria
• BMI 18.5 kg/m2 or greater
• Receiving either neoadjuvant therapy with curative intent (breast cancer patients) or total neoadjuvant therapy with a 5-fluorouracil-based regimen and curative intent (rectal cancer patients)
• Has completed ≤ 4 weeks of neoadjuvant treatment prior to study enrollment
• Willing and able to adhere to the assessments, visit schedules, prohibitions, and restrictions